TEAD2

TEAD2, full name TEA domain transcription factor 2, is also known as TEF-4 or ETF. As a core downstream effector of the Hippo signaling pathway, it forms complexes with YAP/TAZ co-activators to bind TEA/ATTS motifs in target gene promoters, regulating cell proliferation, apoptosis, and organ size control.
Aberrant TEAD2 activity links to cancers like lung and breast cancer, where hyperactivated TEAD-YAP signaling drives tumor growth. Preclinical studies have identified inhibitors (e.g., Verteporfin) disrupting TEAD-YAP interaction, showing therapeutic potential, though clinical trials are still in early stages.